Skip to Content
  • Intermune: Right Back Down Again

    Back in March, Intermune’s stock saw a sudden jump on news that an FDA advisory committee treated their drug pirfenidone more positively than expected. Bu… Read More
  • Garage Biotech

    Freeman Dyson has written about his belief that molecular biology is becoming a field where even basement tinkerers can accomplish things. Whether we’re r… Read More
  • Intermune’s Rise

    If you want to know why people continue to speculate in biotech stocks, just take a look at the stairsteppy last few days of trading in Intermune (ITMN). Last T… Read More
  • Vaccines in the Court

    The Supreme Court has agreed to hear a vaccine-liability case, in an attempt to untangle conflicting lower court rulings. This all turns on the 1986 act that sh… Read More
  • HER2 Confusion

    For years now, drug companies and journalists have been touted the new era of personalized medicine. This is one of those things that always seems to be arrivin… Read More
  • Avandia: Off the Market or Not?

    The Senate report that leaked on Avandia (rosiglitazone) over the weekend has made plenty of headlines. It quotes an internal FDA report that recommends flatly… Read More
Page 20 of 23« First...10...1819202122...Last »